Time to Consider the Compromised!

As COVID-19 restrictions lift and life returns to a new normal for many in society, the lives of immunocompromised (IC) blood cancer patients remain at risk since more than 1 in 4 do not produce antibodies against COVID-19 even after a full course of vaccinations.

These patients carry a high risk of infection, severe disease course and death, and suffer from psychological side-effects due to prolonged shielding.

To help drive change in health policy & protect those who can't protect themselves the International COVID-19 Blood Cancer Coalition calls on YOU as a policy maker to:

1. Ensure access to pre- and post-exposure prophylaxis and antivirals for high-risk IC blood cancer patients.
2. Make access to vaccinations and additional doses a policy for these patients.
3. Facilitate access to fast response COVID-19 testing for high-risk IC patients.
4. Promote access to psychological and psycho-oncological services specifically for IC blood cancer patients who need to continue shielding despite the relaxation of public safety measures.

In their joint statement, more than 70 researchers, clinicians, patient organisations and medical societies urge stakeholders to consider IC blood cancer patients in health policy decisions.

About the ICBCC:

A multi-stakeholder coalition, the International COVID-19 Blood Cancer Coalition, calls upon decision-makers in health policy and care to enable access to IC blood cancer patients to life-saving therapies, and to drive change to accommodate the needs of those patients in general and particularly during the COVID-19 pandemic.

ICBCC
International COVID-19 Blood Cancer Coalition

Find out more at icbcc.info

#considerthecompromised #icbcc